Core Insights - The company has significantly improved its profitability, with total revenue reaching 1.429 billion yuan, a year-on-year increase of 3.37%, and net profit attributable to shareholders soaring by 120.35% to 630 million yuan [1] - The company has demonstrated excellent cost control, with total selling, administrative, and financial expenses amounting to -21.8736 million yuan, a reduction of 347.14% year-on-year [2] - The company's cash flow situation has improved markedly, with operating cash flow per share at 1.63 yuan, a year-on-year increase of 1221.64% [3] - The company's debt structure has been optimized, with interest-bearing liabilities decreasing from 160 million yuan in 2024 to 4.2051 million yuan in 2025, a reduction of 97.37% [4] - The main business analysis shows that anhydride and ester products contributed 88.38% of revenue, reaching 1.263 billion yuan, with a gross margin of 58.38% [5] - In the domestic market, the company achieved sales revenue of 850 million yuan, accounting for 59.47% of total revenue, while in the international market, sales revenue was 579 million yuan, making up 40.53% of total revenue [6] - The company is well-positioned for future growth in the specialty fine chemical sector, leveraging its technological, managerial, and brand advantages [7]

长江商报消息 ●长江商报记者 沈右荣 10倍大牛股正丹股份（300641.SZ）年报正式出炉，堪称爆表。 4月15日晚，正丹股份如期披露了2024年年度报告，公司实现营业收入34.80亿元，同比增长126.31%；归属于母公 司股东的净利润（以下简称"归母净利润"）11.90亿元，同比增长约119倍；扣除非经常性损益的净利润（简称"扣 非净利润"）11.84亿元，同比增长约253倍。 正丹股份全年业绩大幅增长，属于意料之中。从2024年第二季度开始，公司季度归母净利润同比均以超10倍的速 度增长。 从单个季度方面看，2024年一、二、三、四季度，公司实现的营业收入分别为5.18亿元、8.64亿元、12.14亿元、 8.84亿元，同比增长28.80%、155.08%、214.25%、115.40%；归母净利润分别为0.59亿元、2.27亿元、5.39亿元、 暴增的业绩，与市场因素相关，也与公司产能释放直接相关。 2024年，美国TMA（偏苯三酸酐）生产厂家宣布永久性地关闭生产线，海外市场对中国TMA需求增长显著。正丹 股份的主要产品TMA销售数量及价格同比大幅增长。 与归母净利润大幅增长相对应的是，2024年， ...